Skip to main content

NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.

Publication ,  Journal Article
Shah, MH; Goldner, WS; Halfdanarson, TR; Bergsland, E; Berlin, JD; Halperin, D; Chan, J; Kulke, MH; Benson, AB; Blaszkowsky, LS; Eads, J ...
Published in: J Natl Compr Canc Netw
June 2018

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, and paragangliomas. Management of NETs relies heavily on the site of the primary NET. These NCCN Guidelines Insights summarize the management options and the 2018 updates to the guidelines for locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, and thymus primary NETs.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2018

Volume

16

Issue

6

Start / End Page

693 / 702

Location

United States

Related Subject Headings

  • United States
  • Societies, Medical
  • Oncology & Carcinogenesis
  • Neuroendocrine Tumors
  • Medical Oncology
  • Humans
  • Delivery of Health Care, Integrated
  • Adult
  • Adrenal Gland Neoplasms
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., … Zuccarino-Catania, G. (2018). NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw, 16(6), 693–702. https://doi.org/10.6004/jnccn.2018.0056
Shah, Manisha H., Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, et al. “NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.J Natl Compr Canc Netw 16, no. 6 (June 2018): 693–702. https://doi.org/10.6004/jnccn.2018.0056.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 Jun;16(6):693–702.
Shah, Manisha H., et al. “NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.J Natl Compr Canc Netw, vol. 16, no. 6, June 2018, pp. 693–702. Pubmed, doi:10.6004/jnccn.2018.0056.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 Jun;16(6):693–702.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

June 2018

Volume

16

Issue

6

Start / End Page

693 / 702

Location

United States

Related Subject Headings

  • United States
  • Societies, Medical
  • Oncology & Carcinogenesis
  • Neuroendocrine Tumors
  • Medical Oncology
  • Humans
  • Delivery of Health Care, Integrated
  • Adult
  • Adrenal Gland Neoplasms
  • 4203 Health services and systems